THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
CANONICAL MONOGRAPH [8.1] • ID: TIP-MED-000129

1. Amoxicillin Trihydrate

2. Pharmacological Class: Aminopenicillin Beta-Lactam Antibiotic (Bactericidal Cell-Wall Peptidoglycan Synthesis Inhibitor; WHO 'Access' Group) • 3. Therapeutic Category: Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08)

āš–ļø Compare Medicine

4. Clinical Overview & Verified Formulation Identity

Generic Name & Identifier:
Amoxicillin Trihydrate
Code: [8.1] | Stable ID: TIP-MED-000129
Verified Indian Market Brands / Status:
Mox (Sun Pharma), Novamox (Cipla), Almox (Alkem)
9. Dosage Forms & Strengths:
Oral Capsules / Dispersible Tablets: 250 mg, 500 mg; Paediatric Dry Syrup for Reconstitution: 125 mg/5 mL, 250 mg/5 mL; Drops: 100 mg/mL
Route: Oral / Parenteral / Topical as specified by formulation
Indian Regulatory Schedule & NLEM Status:
Schedule H (Drugs Rules, 1945 — Prescription Only)
True

5 & 6. Mechanism of Action & Pharmacodynamics

Bactericidal time-dependent beta-lactam antibiotic (`fT > MIC`) that binds to bacterial Penicillin-Binding Proteins (PBPs 1A, 2, 3), inhibiting transpeptidation of peptidoglycan cell-wall cross-links and triggering autolysin-mediated bacterial cell lysis.

8. Therapeutic Indications

10. Dosage and Administration (Educational Reference Summary)

Dosing & Clinical Context: Educational Reference Summary: Standard adult oral regimen is 250 mg to 500 mg every 8 hours (TID) or 875 mg every 12 hours (BID) for 5–7 days depending on infection site and severity (H. pylori: 1000 mg BID).
Administration & Timing: May be taken with or without food (taking at the start of a light meal improves GI tolerability, particularly when combined with Clavulanic Acid). Space doses evenly every 8 hours (`fT > MIC` time-dependent killing).

11 & 13. Contraindications, Precautions and Warnings

🚫 11. Contraindications:
  • History of immediate IgE-mediated hypersensitivity (anaphylaxis, angioedema, bronchospasm, Stevens-Johnson syndrome) to Penicillins or any Beta-Lactam antibiotic
  • Avoid in suspected infectious mononucleosis (Epstein-Barr virus) due to >70% incidence of generalised maculopapular morbilliform rash
āš ļø 13. Precautions and Warnings:

No routine hepatic dose adjustment required for plain Amoxicillin (monitor LFTs if co-formulated with Clavulanate, which carries cholestatic jaundice risk).

7, 12, 14–18. Detailed Pharmacokinetics, Interactions, Special Populations & Counselling

7 & 16. Pharmacokinetics (ADME) & Renal / Hepatic Considerations

7. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion): Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.

16a. Renal Considerations: Excreted primarily unchanged via glomerular filtration and tubular secretion: CrCl 10–30 mL/min: 250–500 mg every 12 hours; CrCl < 10 mL/min: 250–500 mg every 24 hours; administer dose after haemodialysis session.

16b. Hepatic Considerations: No routine hepatic dose adjustment required for plain Amoxicillin (monitor LFTs if co-formulated with Clavulanate, which carries cholestatic jaundice risk).

12 & 14. Adverse Effects & Drug Interactions
12. Adverse Effects:
  • Hypersensitivity reactions ranging from delayed maculopapular rash to immediate IgE-mediated urticaria and anaphylaxis
  • Diarrhoea, nausea, candidal superinfection (oral/vulvovaginal thrush), rare Clostridioides difficile colitis
14. Drug Interactions:
  • Methotrexate: Penicillins compete for renal organic anion tubular secretion (OAT1/OAT3), reducing Methotrexate clearance and risking severe myelosuppression.
  • Allopurinol: Co-administration significantly increases the incidence of non-allergic maculopapular skin rash.
  • Warfarin / Oral Anticoagulants: Alteration of gut flora may potentiate INR elevation; monitor INR during systemic antibiotic therapy.
15, 17 & 18. Special Populations, Clinical Monitoring & Patient Counselling

15. Use in Special Populations (Pregnancy, Lactation, Paediatrics, Geriatrics): Evaluate maternal-foetal benefit-risk ratio, paediatric mg/kg ceiling, and geriatric renal function prior to prescribing.

17. Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

18. Patient Counselling & Storage:
  • Always confirm absence of Penicillin allergy before dispensing the first dose.
  • Complete the full prescribed antibiotic course at evenly spaced intervals (every 8 hours for TID) even if fever subsides after 48 hours.
  • For paediatric dry syrup powder: reconstitute to the ring mark with boiled and cooled water, shake well before each dose, and discard unused suspension after 7–10 days (per manufacturer label).

Storage & Dispensing Notes: Store capsules below 25°C in a dry place; reconstituted oral suspensions should be stored in a cool place / refrigerator (2°C–8°C) and discarded after 7–14 days.

Visual Pharmacology Illustration (PLATE-8.9)

ANTIBACTERIAL MECHANISMS OF ACTION: CELL WALL, 30S/50S RIBOSOME, DNA & FOLATE 1. Cell-Wall Synthesis (Bactericidal) • Beta-Lactams (Penicillins, Cephalosporins, Meropenem): Inhibit PBPs (Transpeptidase) • Vancomycin: Binds D-Ala-D-Ala peptide • Fosfomycin: Inhibits MurA enolpyruvyl PK/PD: Time-dependent (fT > MIC) 2. 30S Ribosomal Subunit • Aminoglycosides (Gentamicin, Amikacin): Irreversible 30S binding & mRNA misreading (Bactericidal; Cmax/MIC; Ototoxic/Nephrotoxic) • Tetracyclines (Doxycycline) & Tigecycline: Block aminoacyl-tRNA binding at 30S A-site 3. 50S Ribosomal Subunit • Macrolides (Azithromycin, Clarithromycin) & Clindamycin: Block 23S rRNA translocation • Linezolid: Blocks 70S initiation complex (MRSA/VRE) • Chloramphenicol: Inhibits peptidyl transferase Mostly bacteriostatic (Linezolid vs Staph/Strep) 4. Nucleic Acid Synthesis (DNA Gyrase & RNA Pol) • Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin): Inhibit DNA Gyrase (Topoisomerase II) & Topoisomerase IV (Bactericidal) • Rifampicin: Inhibits bacterial DNA-dependent RNA polymerase (β-subunit) • Metronidazole: Reduced nitro group forms free radicals that strand-break DNA 5. Folate Pathway & Cell Membrane Disruptors • PABA → [Sulfamethoxazole blocks Dihydropteroate Synthase] → Dihydrofolate • Dihydrofolate → [Trimethoprim blocks DHFR] → Tetrahydrofolate (Co-trimoxazole) • Polymyxins (Colistin): Bind LPS outer membrane of MDR Gram-negative bacilli • Daptomycin: Ca2+-dependent membrane depolarisation of Gram-positive cocci (MRSA)
Figure 8.9: Mechanisms of action of major antibacterial classes across bacterial cell-wall synthesis, 30S/50S ribosomal protein translation, nucleic acid replication, and folic acid biosynthesis.

19. Authoritative References & Source Traceability

Primary Reference Record: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) by Tejas Nartam; ICMR Antimicrobial Treatment Guidelines; NFI 7th Ed (2026).

Verification Portals: Indian Pharmacopoeia Commission (IPC) • CDSCO (India Jurisdiction) • NCBI Bookshelf • DailyMed (US FDA Label Reference)

Last Reviewed Date: 2026-11-08 • Related Study Guide: Antimicrobial Stewardship & PK/PD Optimization →